List of investigational hair loss drugs

This is a list of investigational hair loss drugs, or drugs that are currently under development for clinical use in the treatment of different forms of alopecia (hair loss), such as androgenetic alopecia (pattern hair loss) and alopecia areata (spot baldness), but are not yet approved.

Chemical/generic names are listed first, with developmental code names, synonyms, and brand names in parentheses. The format of list items is "Name (Synonyms) – Route – Indication – Mechanism of Action [Reference]".

This list was last comprehensively updated in July 2025. It is likely to become outdated with time.

Under development

Preregistration

  • Coacillium (LH-8) – topical, other routes – alopecia areata, alopecia – various mechanisms of action [1]
  • Gecaxitinib (gecacitinib, jaktinib) – oral – alopecia areata – ACVR1 protein inhibitor, Janus kinase 1 inhibitor, Janus kinase 2 inhibitor, Janus kinase 3 inhibitor, TYK2 kinase inhibitor [2]
  • Ivarmacitinib (ARQ-252, ARQ-255, SHR-0302) – oral – alopecia areata – Janus kinase 1 inhibitor [3]

Phase 3

  • AB-103 – topical – alopecia – minoxidil sulfotransferase stimulant (adjunct to minoxidil) [4]
  • Clascoterone (Breezula, Winlevi; CB-03-01) – topical – alopecia – androgen receptor antagonist [5]
  • Diphencyprone (diphenylcyclopropenone, samcyprone) – topical – alopecia areata – immunomodulator [6]
  • Dutasteride (AD-208) – oral – alopecia – 5α-reductase inhibitor [7]
  • Minoxidil oral extended-release (VDPHL01, VDPHL-01, VDPHL) – oral – alopecia, male pattern baldness – potassium channel opener (prodrug of minoxidil sulfate)[8][9][10][11]
  • Minoxidil sublingual (SLM) – sublingual – alopecia – potassium channel opener (prodrug of minoxidil sulfate)[12][13]
  • Pyrilutamide (EX-A5504, HY-145451, KX 826) – topical – alopecia – androgen receptor antagonist [14]
  • Upadacitinib (Rinvoq; ABT-494) – oral – alopecia areata – Janus kinase 1 inhibitor [15]

Phase 2/3

  • Dalosirvat (SM-04554) – topical – alopecia – Wnt signalling pathway stimulant [16]

Phase 2

  • Abatacept (Orencia) – injection – alopecia areata – T cell activation inhibitor [17]
  • Amlitelimab (KY-1005, SAR-445229) – subcutaneous injection – alopecia areata – OX40 ligand inhibitor [18]
  • BAY-1158061 (HMI-115) – subcutaneous injection – alopecia – prolactin receptor monoclonal antibody (prolactin receptor inhibitor) [19]
  • Bempikibart (ADX-914, BMS-986265) – subcutaneous injection – alopecia areata – CRLF2 protein antagonist, interleukin 7 receptor α subunit inhibitor [20]
  • Bimatoprost (Lumigan) – topical – alopecia – prostaglandin F2α receptor agonist [21]
  • Botulinum toxin A (Xeomin; incobotulinum toxin A) – intradermal – alopecia – acetylcholine release inhibitor and neuromuscular blocking agent [22]
  • CKD-498 – oral – alopecia – undefined mechanism of action [23]
  • Daxdilimab (HZN-7734; MEDI-7734; VIB-7734) – oral – alopecia areata – anti-ILT7 human monoclonal antibody/dendritic cell inhibitor [24]
  • Delgocitinib (Anzupgo, Corectim; JTE-052, LEO-124249, LP-0133) – unknown – alopecia areata – Janus kinase inhibitor [25]
  • Deucravacitinib (Sotyktu; BMS-986165) – oral – alopecia areata – TYK2 kinase inhibitor [26]
  • Finasteride/latanoprost/minoxidil (TH-07; Triple Hair) – topical – alopecia – combination drug/multiple mechanisms of action [27]
  • FOL-005 (osteopontin-derived peptide) – intradermal – alopecia – undefined mechanism of action [28]
  • GT-20029 (AR-PROTAC) – topical – alopecia – androgen receptor degradation enhancer [29]
  • KL-130008 – oral – alopecia areata – Janus kinase inhibitor [30]
  • NXC-736 – oral – alopecia areata – sphingosine 1 phosphate receptor antagonist [31]
  • PP405 (PP-405) – topical – alopecia – mitochondrial pyruvate carrier (MPC) inhibitor [32][33]
  • Rezpegaldesleukin (Rezpeg; LY-3471851, NKTR-358) – unknown – alopecia areata – interleukin-2 conjugate/modulator [34]
  • RK-023 (nobiprostolan) – topical – alopecia, hypotrichosis – undefined mechanism of action (prostaglandin F2α analogue) [35]
  • Rosnilimab (ANB-030) – subcutaneous injection – alopecia areata – programmed cell death 1 receptor agonist [36]
  • Ruxolitinib (Jakafi, Jakavi, Opzelura; INCB-018424) – topical – alopecia areata – Janus kinase 1 inhibitor, Janus kinase 2 inhibitor [37]
  • SIS-302-AA – unspecified – alopecia areata – undefined mechanism of action [38]
  • SYHX-1901 – oral – alopecia areata – Janus kinase inhibitor, Syk kinase inhibitor [39]
  • TDM-105795 (CU-40101) – topical – alopecia – thyroid hormone receptor agonist [40]

Phase 1/2

  • ABS-201 – subcutaneous injection – alopecia – prolactin receptor monoclonal antibody [41][42][43]
  • Finasteride (IVL-3001, IVL-3002) – long-acting injection – alopecia – 5α-reductase inhibitor [44]
  • Finasteride (DA-4001, DA-4001C) – topical – alopecia – 5α-reductase inhibitor [45]
  • IMG-007 (HMPL-A28) – intravenous injection – alopecia areata – OX40 receptor antagonist [46]

Phase 1

  • AH-001 – topical – alopecia – ubiquitin-protein ligase expression stimulant [47]
  • AMP-303 – intradermal – alopecia – undefined mechanism of action (polysaccharide) [48]
  • CKD-843 – oral, injection – alopecia – undefined mechanism of action [49]
  • CKR-051 – transdermal – alopecia – CXXC5 protein inhibitor, Wnt signalling pathway stimulant [50]
  • DR-01 – parenteral – alopecia areata – antibody-dependent cell cytotoxicity, T lymphocyte stimulant [51]
  • ET-02 (RS-5441) – topical – alopecia, hair disorders – undefined mechanism of action (targets and restores hair follicle stem cells) [52][53][54]
  • FOL-100 – topical – alopecia – undefined mechanism of action [55]
  • OLX-72021 – intradermal injection – alopecia – RNA interference [56]
  • QY-201 – oral – alopecia areata – Janus kinase 1 inhibitor, TYK2 kinase inhibitor [57]
  • SCO-240 – oral – alopecia – somatostatin receptor 5 modulator [58]
  • Squaric acid dibutyl ester (SQX-770) – topical – alopecia areata – immunomodulator [59]
  • VDAA – topical – alopecia areata – undefined mechanism of action [60]

Phase 0

  • Latanoprost/minoxidil (ANR-001.1) – topical – hypotrichosis – combination drug/multiple mechanisms of action [61]

Preclinical

  • AC-203 – unspecified – alopecia areata – cell death modulator [62]
  • ADA-308 – topical – alopecia – androgen receptor antagonist [63]
  • BMD-1141 (BMD-1341) – subcutaneous injection – alopecia – parathyroid hormone receptor agonist [64]
  • Crebankitug (ZB-168) – parenteral – alopecia areata – interleukin 7 receptor α subunit inhibitor, thymic stromal lymphopoietin inhibitor [65]
  • CS-12192 – oral – alopecia areata – Janus kinase 1 inhibitor, Janus kinase 3 inhibitor, TBK1 protein inhibitor [66]
  • ES-135 – parenteral – alopecia – fibroblast growth factor replacement [67]
  • FB-102 – unknown – alopecia areata – interleukin-2 receptor β subunit antagonist [68]
  • HCW-9302 – injection – alopecia areata – interleukin 2 replacement [69]
  • MAX-40070 (MAX-3) – topical – alopecia areata – Janus kinase inhibitor, TYK2 kinase inhibitor [70]
  • MEI-004 – unknown – alopecia – undefined mechanism of action [71]
  • Oxymetazoline (DA-020) – topical – alopecia – α1-adrenergic receptor agonist [72]
  • Phenylephrine/synephrine/tyramine (DA-007) – topical – alopecia – combination of phenylephrine (α1-adrenergic receptor agonist), synephrine (α1-adrenergic receptor agonist), and tyramine (norepinephrine–dopamine releasing agent) [73][74]
  • YR-001 – topical – alopecia – ion channel antagonist [75]

Research

  • SP-16 (Serpin Peptide 16) – unspecified – alopecia areata – immunomodulator, LDL receptor agonist [76]
  • TRN-007 – unspecified – hair disorders – RNA interference [77]

Phase unknown

  • JV-HG1 – topical – hair disorders – undefined mechanism of action [78]
  • OMA-102 – oral – alopecia – undefined mechanism of action [79]

Not under development

Development suspended

  • EQ-101 (BNZ132) – intravenous – alopecia areata – interleukin 15 receptor antagonist, interleukin 2 receptor antagonist, interleukin 9 receptor antagonist [80]
  • Research programme: SNA based alopecia therapeutics - Exicure/AbbVie – alopecia – gene expression modulators [81]
  • XCUR-17 – topical – alopecia – RNA interference [82]

No development reported

  • AB-101 (RJ-101) – topical – alopecia – undefined mechanism of action [83]
  • BRM-421 (GPN-00136, PDSP) – topical – alopecia – cell proliferation stimulant [84]
  • Dimethylcurcumin (ASC-J9, AJ-101) – topical – male pattern baldness – androgen receptor degradation enhancer [85]
  • Lepzacitinib (ATI-1777) – topical – alopecia areata – Janus kinase 1 inhibitor, Janus kinase 3 inhibitor [86]
  • PF-277343 – unspecified – alopecia – undefined mechanism of action [87]
  • Research programme: janus kinase inhibitors - Aclaris Therapeutics/ JAKPharm – unknown – alopecia areata – Janus kinase 3 inhibitors [88]
  • Research programme: skin diseases therapeutics - Quark Pharmaceuticals (QP-AL1; QP-AL2) – unknown – alopecia (chemotherapy-induced) – RNA interference [89]
  • Research programme: stem cell therapeutics - Histostem (Cirrhosis HMScs) – unknown – alopecia – cell replacement [90]
  • Synephrine (AB-102) – topical – alopecia – α1-adrenergic receptor agonist [91][92]
  • Valproic acid (VPA spray) – topical – male pattern baldness – glycogen synthase kinase 3β inhibitor, Wnt signalling pathway stimulant [93]

Discontinued

  • AS-601811 – oral – male pattern baldness – 5α-reductase inhibitor [94]
  • ATI-501 (A-201; ATI-50001) – oral – alopecia areata – Janus kinase 1 inhibitor, Janus kinase 3 inhibitor [95]
  • Brepocitinib (PF-06700841) – oral – alopecia, alopecia areata – Janus kinase 1 inhibitor, TYK2 kinase inhibitor [96]
  • Cioteronel (CPC-10997; Cyoctol, X-Andron) – topical – alopecia – androgen receptor antagonist [97]
  • Denileukin diftitox (Lymphirtm, Ontak, Remitoro; LY-335348; DAB389 interleukin-2) – unknown – alopecia – protein synthesis inhibitor [98]
  • Epristeride (Aipuliete; ONO-9302, SKF-105657) – oral – alopecia – 5α-reductase inhibitor [99]
  • Etrasimod (Verespiti, Velspity; APD-334, PF-07915503) – oral – alopecia areata – sphingosine 1 phosphate receptor modulator [100]
  • Farudodstat (ASLAN-003, LAS-186323) – oral – alopecia areata – dihydroorotate dehydrogenase inhibitor [101]
  • HST-001 (HSC-660) – intradermal – alopecia – intercellular signalling peptide and protein replacement [102]
  • Ifidancitinib (A-301, ATI-50002, ATI-502) – topical – alopecia, alopecia areata – Janus kinase 1 inhibitor, Janus kinase 3 inhibitor [103]
  • MK-434 (MK-0434) – oral – alopecia – 5α-reductase inhibitor [104]
  • Naminidil (BMS-234303) – topical – alopecia – potassium channel opener [105]
  • NEOSH–101 – topical – alopecia – undefined mechanism of action [106]
  • P-1075 – unknown – alopecia – potassium channel opener [107]
  • Piliel – topical – alopecia – undefined mechanism of action [108]
  • Research programme: androgen receptor antagonists - Endoceutics (EM-4350, EM-6537) – unknown – male pattern baldness – androgen receptor antagonists [109]
  • Research programme: oligonucleotide therapeutics for alopecia - OliPass – unknown – alopecia – androgen receptor antagonists [110]
  • RU-58841 (PSK-3841, HMR-3841) – topical – alopecia – androgen receptor antagonist [111]
  • Secukinumab (Cosentyx) – injection – alopecia areata – IL17A protein inhibitor [112]
  • Setipiprant (ACT-129968, KYTH-105) – oral – alopecia – prostaglandin D2 receptor antagonist [113]
  • Timbetasin (thymosin β4) – unknown – alopecia – various mechanisms of action [114]
  • Tralokinumab (Adbry, Adtralza; CAT-354, LP-0162) – subcutaneous injection – alopecia areata – interleukin-13 inhibitor [115]
  • TU-2100 – topical – hair disorders – undefined mechanism of action [116]

Clinically used drugs

Approved drugs

Potassium channel openers

5α-Reductase inhibitors

Androgen receptor antagonists

  • Topilutamide (fluiridil; Eucapil) – topical – alopecia – androgen receptor antagonist[122]

Immunomodulators

  • Baricitinib (Olumiant) – oral – alopecia areata – Janus kinase 1 inhibitor, Janus kinase 2 inhibitors, TYK2 kinase inhibitor [123]
  • Deuruxolitinib (Leqselvi) – oral – alopecia areata – Janus kinase 1 inhibitor, Janus kinase 2 inhibitor [124]
  • Ritlecitinib (Litfulo) – oral – alopecia areata – Emt protein-tyrosine kinase inhibitor, Janus kinase 3 inhibitor [125]

Others

  • Alfatradiol (Avicis, Avixis, Ell-Cranell Alpha, Pantostin) – oral – alopecia – dual weak estrogen and 5α-reductase inhibitor[122]
  • Minoxidil/finasteride (MorrF) – topical – alopecia – combination of minoxidil (potassium channel opener) and finasteride (5α-reductase inhibitor) [126]
  • Nepidermin (Easyef; DWP-401) – topical – alopecia – recombinant human epidermal growth factor (rhEGF) or epidermal growth factor receptor (EGFR) agonist [127]

Off-label drugs

See also

References

  1. ^ "Coacillium - Legacy Healthcare - AdisInsight". adisinsight.springer.com.
  2. ^ "Gecaxitinib hydrochloride - Suzhou Zelgen Biopharmaceuticals - AdisInsight". adisinsight.springer.com.
  3. ^ "Ivarmacitinib - Arcutis Biotherapeutics/Jiangsu HengRui Medicine - AdisInsight". adisinsight.springer.com.
  4. ^ "AB 103 - AdisInsight". adisinsight.springer.com.
  5. ^ "Clascoterone - Cosmo Pharmaceuticals - AdisInsight". adisinsight.springer.com.
  6. ^ "Diphencyprone - Phio Pharmaceuticals - AdisInsight". adisinsight.springer.com.
  7. ^ "Dutasteride - Addpharma - AdisInsight". adisinsight.springer.com.
  8. ^ "VDPHL - AdisInsight". adisinsight.springer.com.
  9. ^ Hebebrand, Maddi (October 23, 2025). "Extended-Release Minoxidil Shows Promise in AGA". Dermatology Times. Retrieved October 23, 2025.
  10. ^ Segal, Lindy (October 16, 2025). "A New Oral Minoxidil May Be FDA-Approved for Hair Loss: What to Know". Harper's BAZAAR. Retrieved October 23, 2025.
  11. ^ a b Modha JD, Pathania YS (November 2022). "Comprehensive review of oral minoxidil in alopecia". J Cosmet Dermatol. 21 (11): 5527–5531. doi:10.1111/jocd.15324. PMID 36065675.
  12. ^ "Sublingual minoxidil". AdisInsight. September 22, 2025. Retrieved October 29, 2025.
  13. ^ Samson Clinical (August 6, 2025). "First Patient Randomised in Samson Clinical Phase III Sublingual Minoxidil Trial for Male Pattern Hair Loss (Androgenetic Alopecia)". PR Newswire. Retrieved October 29, 2025.
  14. ^ "Pyrilutamide - Suzhou Kintor Pharmaceuticals - AdisInsight". adisinsight.springer.com.
  15. ^ "Upadacitinib - AbbVie - AdisInsight". adisinsight.springer.com.
  16. ^ "Dalosirvat - Biosplice Therapeutics - AdisInsight". adisinsight.springer.com.
  17. ^ "Abatacept - Bristol-Myers Squibb - AdisInsight". adisinsight.springer.com.
  18. ^ "Amlitelimab - Kymab/Sanofi - AdisInsight". adisinsight.springer.com.
  19. ^ "BAY 1158061 - AdisInsight". adisinsight.springer.com.
  20. ^ "Bempikibart - Q32 Bio - AdisInsight". adisinsight.springer.com.
  21. ^ "Bimatoprost - AbbVie - AdisInsight". adisinsight.springer.com.
  22. ^ "Botulinum toxin A - Merz Pharma - AdisInsight". adisinsight.springer.com.
  23. ^ "CKD 498 - AdisInsight". adisinsight.springer.com.
  24. ^ "Daxdilimab - Horizon Therapeutics - AdisInsight". adisinsight.springer.com.
  25. ^ "Delgocitinib - LEO Pharma - AdisInsight". adisinsight.springer.com.
  26. ^ "Deucravacitinib - Bristol-Myers Squibb - AdisInsight". adisinsight.springer.com.
  27. ^ "Finasteride/latanoprost/minoxidil - Triple Hair - AdisInsight". adisinsight.springer.com.
  28. ^ "FOL 005 - AdisInsight". adisinsight.springer.com.
  29. ^ "GT 20029 - AdisInsight". adisinsight.springer.com.
  30. ^ "KL 130008 - AdisInsight". adisinsight.springer.com.
  31. ^ "NXC 736 - AdisInsight". adisinsight.springer.com.
  32. ^ "PP 405 - AdisInsight". adisinsight.springer.com.
  33. ^ Brown, Lane (August 12, 2025). "The Great Unbalding Draws Nearer". Intelligencer. Retrieved October 23, 2025.
  34. ^ "Rezpegaldesleukin - Nektar Therapeutics - AdisInsight". adisinsight.springer.com.
  35. ^ "RK 023". AdisInsight.
  36. ^ "Rosnilimab - AnaptysBio - AdisInsight". adisinsight.springer.com.
  37. ^ "Ruxolitinib - Incyte Corporation/Novartis". adisinsight.springer.com.
  38. ^ "SIS 302 AA - AdisInsight". adisinsight.springer.com.
  39. ^ "SYHX 1901 - AdisInsight". adisinsight.springer.com.
  40. ^ "TDM 105795 - AdisInsight". adisinsight.springer.com.
  41. ^ "ABS 201". AdisInsight. October 7, 2025. Retrieved November 14, 2025.
  42. ^ Frederickson, Emma (October 20, 2025). "A New Hair Loss Drug Could Cure Balding and Reverse Graying". Popular Mechanics. Retrieved November 14, 2025.
  43. ^ Zacks (December 5, 2025). "ABSI Stock Up on Initiating Dosing in Androgenetic Alopecia Study". Nasdaq. Retrieved December 30, 2025.{{cite news}}: CS1 maint: url-status (link)
  44. ^ "Finasteride - Inventage Lab - AdisInsight". adisinsight.springer.com.
  45. ^ "Finasteride topical - Dong-A ST - AdisInsight". adisinsight.springer.com.
  46. ^ "IMG 007 - AdisInsight". adisinsight.springer.com.
  47. ^ "AH 001 - AdisInsight". adisinsight.springer.com.
  48. ^ "AMP 303 - AdisInsight". adisinsight.springer.com.
  49. ^ "CKD 843 - AdisInsight". adisinsight.springer.com.
  50. ^ "CKR 051 - AdisInsight". adisinsight.springer.com.
  51. ^ "DR 01 - AdisInsight". adisinsight.springer.com.
  52. ^ "RS 5441". AdisInsight. July 28, 2025. Retrieved September 22, 2025.
  53. ^ "Delving into the Latest Updates on ET-02(Eirion Therapeutics) with Synapse". Synapse. September 20, 2025. Retrieved September 22, 2025.
  54. ^ Bosslett, Marie; Edelson, Jon (January 14, 2025). "The Unprecedented Phase 1 Results of ET-02 for the Treatment of Androgenic Alopecia". Dermatology Times. Retrieved September 22, 2025.
  55. ^ "FOL 100 - AdisInsight". adisinsight.springer.com.
  56. ^ "OLX 72021 - AdisInsight". adisinsight.springer.com.
  57. ^ "QY 201 - AdisInsight". adisinsight.springer.com.
  58. ^ "SCO 240 - AdisInsight". adisinsight.springer.com.
  59. ^ "Squaric acid dibutyl ester - Squarex - AdisInsight". adisinsight.springer.com.
  60. ^ "VDAA - AdisInsight". adisinsight.springer.com.
  61. ^ "Latanoprost/minoxidil - Aneira Pharma - AdisInsight". adisinsight.springer.com.
  62. ^ "AC 203 - Accropeutics - AdisInsight". adisinsight.springer.com.
  63. ^ "ADA 308 - Aranda Pharma - AdisInsight". adisinsight.springer.com.
  64. ^ "BMD 1141 - AdisInsight". adisinsight.springer.com.
  65. ^ "Crebankitug - Zura Bio - AdisInsight". adisinsight.springer.com.
  66. ^ "CS 12192 - AdisInsight". adisinsight.springer.com.
  67. ^ "ES 135 - AdisInsight". adisinsight.springer.com.
  68. ^ "FB 102 - AdisInsight". adisinsight.springer.com.
  69. ^ "HCW 9302 - AdisInsight". adisinsight.springer.com.
  70. ^ "MAX 40070 - AdisInsight". adisinsight.springer.com.
  71. ^ "MEI 004 - AdisInsight". adisinsight.springer.com.
  72. ^ "Oxymetazoline". AdisInsight. March 3, 2026. Retrieved March 13, 2026.
  73. ^ "DA 007 - AdisInsight". adisinsight.springer.com.
  74. ^ "DA-007 Advanced Drug Monograph". MedPath. June 10, 2025. Retrieved March 13, 2026. DA-007 is an investigational small molecule drug, formulated as a topical solution, currently under development by Applied Biology Inc. It is a combination of three alpha 1 (α1​) adrenergic receptor agonists: Phenylephrine, Tyramine, and Synephrine.[3] The primary therapeutic goal of DA-007 is the prevention of Chemotherapy-Induced Alopecia (CIA), a common and distressing side effect of many cancer treatments, particularly in female breast cancer patients undergoing taxane and/or anthracycline-based chemotherapy regimens.[3] The mechanism of action of DA-007 is based on inducing localized vasoconstriction in the scalp. By activating α1-adrenergic receptors on the scalp vasculature, DA-007 aims to reduce local blood perfusion, thereby limiting the delivery of cytotoxic chemotherapeutic agents to the rapidly dividing cells of the hair follicles.[5] This targeted pharmacological approach offers a potential alternative to physical methods like scalp cooling, potentially providing improved convenience and tolerability for patients. The selection of a multi-component formulation suggests a strategy to achieve a more {{cite web}}: zero width space character in |quote= at position 177 (help)
  75. ^ "YR 001 - AdisInsight". adisinsight.springer.com.
  76. ^ "SP 16 - AdisInsight". adisinsight.springer.com.
  77. ^ "TRN 007 - AdisInsight". adisinsight.springer.com.
  78. ^ "JV HG1 - AdisInsight". adisinsight.springer.com.
  79. ^ "OMA 102 - AdisInsight". adisinsight.springer.com.
  80. ^ "EQ 101 - AdisInsight". adisinsight.springer.com.
  81. ^ "Research programme: SNA based alopecia therapeutics - Exicure/AbbVie - AdisInsight". adisinsight.springer.com.
  82. ^ "XCUR 17 - AdisInsight". adisinsight.springer.com.
  83. ^ "AB 101 - Safety Shot - AdisInsight". adisinsight.springer.com.
  84. ^ "BRM 421 - AdisInsight". adisinsight.springer.com.
  85. ^ "ASCJ 9". AdisInsight.
  86. ^ "Lepzacitinib - AdisInsight". adisinsight.springer.com.
  87. ^ "PF 277343 - AdisInsight". adisinsight.springer.com.
  88. ^ "Research programme: janus kinase inhibitors - Aclaris Therapeutics/ JAKPharm - AdisInsight". adisinsight.springer.com.
  89. ^ "Research programme: skin diseases therapeutics - Quark Pharmaceuticals - AdisInsight". adisinsight.springer.com.
  90. ^ "Research programme: stem cell therapeutics - Histostem - AdisInsight". adisinsight.springer.com.
  91. ^ "AB 102 - Safety Shot - AdisInsight". adisinsight.springer.com.
  92. ^ McCoy J, Goren A, Kovacevic M, Situm M, Stanimirovic A, Shapiro J, Sinclair R (January 2018). "Styling without shedding: Novel topical formula reduces hair shedding by contracting the arrector pili muscle". Dermatol Ther. 31 (1). doi:10.1111/dth.12575. PMID 29193553.
  93. ^ "Valproic acid topical". AdisInsight.
  94. ^ "AS 601811". AdisInsight.
  95. ^ "ATI 501 - AdisInsight". adisinsight.springer.com.
  96. ^ "Brepocitinib - Priovant Therapeutics - AdisInsight". adisinsight.springer.com.
  97. ^ "Cioteronel - AdisInsight". adisinsight.springer.com.
  98. ^ "Denileukin diftitox - Eisai - AdisInsight". adisinsight.springer.com.
  99. ^ "Epristeride - AdisInsight". adisinsight.springer.com.
  100. ^ "Etrasimod - Pfizer - AdisInsight". adisinsight.springer.com.
  101. ^ "Farudodstat - ASLAN Pharmaceuticals - AdisInsight". adisinsight.springer.com.
  102. ^ "HST 001 - AdisInsight". adisinsight.springer.com.
  103. ^ "Ifidancitinib - Aclaris Therapeutics/Rigel Pharmaceuticals - AdisInsight". adisinsight.springer.com.
  104. ^ "MK 434 - AdisInsight". adisinsight.springer.com.
  105. ^ "Naminidil - AdisInsight". adisinsight.springer.com.
  106. ^ "NEOSH 101 - AdisInsight". adisinsight.springer.com.
  107. ^ "P 1075 - AdisInsight". adisinsight.springer.com.
  108. ^ "Piliel - AdisInsight". adisinsight.springer.com.
  109. ^ "Research programme: androgen receptor antagonists". AdisInsight.
  110. ^ "Research programme: oligonucleotide therapeutics for alopecia - OliPass - AdisInsight". adisinsight.springer.com.
  111. ^ "PSK 3841 - AdisInsight". adisinsight.springer.com.
  112. ^ "Secukinumab - Novartis - AdisInsight". adisinsight.springer.com.
  113. ^ "Setipiprant - Actelion Pharmaceuticals / Kythera Biopharmaceuticals - AdisInsight". adisinsight.springer.com.
  114. ^ "Timbetasin - RegeneRx Biopharmaceuticals - AdisInsight". adisinsight.springer.com.
  115. ^ "Tralokinumab - LEO Pharma - AdisInsight". adisinsight.springer.com.
  116. ^ "TU 2100 - AdisInsight". adisinsight.springer.com.
  117. ^ "Finasteride - Merck & Co. - AdisInsight". adisinsight.springer.com.
  118. ^ a b Dhurat R, Sharma A, Rudnicka L, Kroumpouzos G, Kassir M, Galadari H, Wollina U, Lotti T, Golubovic M, Binic I, Grabbe S, Goldust M (May 2020). "5-Alpha reductase inhibitors in androgenetic alopecia: Shifting paradigms, current concepts, comparative efficacy, and safety". Dermatol Ther. 33 (3) e13379. doi:10.1111/dth.13379. PMID 32279398.
  119. ^ "Finasteride - Polichem - AdisInsight". adisinsight.springer.com.
  120. ^ Zhou C, Yang B, Zeng H, Xia R, Dang N, Yang Q, Li J, Zhang C, Zhang G, Wei A, Lai W, Yang S, Diao Q, Ding Y, Wu L, Liu L, Jia D, Zhu H, Zhang J (March 2025). "Efficacy and safety of topical finasteride spray solution in the treatment of Chinese men with androgenetic alopecia: A phase III, multicenter, randomized, double-blind, placebo-controlled study". Chin Med J (Engl). doi:10.1097/CM9.0000000000003495. PMID 40090937. A new topical spray of finasteride (2.275 mg/mL, 0.25%) using hydroxypropyl chitosan (HPCH) technology has been approved for marketing in Italy (Caretopic®); Spain (Alocare®); Portugal, Germany, Switzerland, Hungary, and the Czech Republic (Fynzur®); Luxembourg, Korea, Saudi Arabia, Slovakia, and Romania (Finjuve®); France (Fincrezo®); and Belgium (Fynzur®) until June 2024.
  121. ^ "Dutasteride - GSK - AdisInsight". adisinsight.springer.com.
  122. ^ a b Varothai S, Bergfeld WF (July 2014). "Androgenetic alopecia: an evidence-based treatment update". Am J Clin Dermatol. 15 (3): 217–230. doi:10.1007/s40257-014-0077-5. PMID 24848508.
  123. ^ "Baricitinib - Eli Lilly and Company/Incyte Corporation - AdisInsight". adisinsight.springer.com.
  124. ^ "Deuruxolitinib - Concert Pharmaceuticals - AdisInsight". adisinsight.springer.com.
  125. ^ "Ritlecitinib - Pfizer - AdisInsight". adisinsight.springer.com.
  126. ^ "Minoxidil/Finasteride - Jina Pharmaceuticals/Intas Pharmaceuticals - AdisInsight". adisinsight.springer.com.
  127. ^ "Nepidermin - AdisInsight". adisinsight.springer.com.
  128. ^ Gupta AK, Talukder M, Shemer A, Piraccini BM, Tosti A (December 2023). "Low-Dose Oral Minoxidil for Alopecia: A Comprehensive Review". Skin Appendage Disord. 9 (6): 423–437. doi:10.1159/000531890. PMC 10806356. PMID 38376087.
  129. ^ Ong MM, Avram M, McMichael A, Tosti A, Lipner SR (May 2025). "Antiandrogen therapy for the treatment of female pattern hair loss: A clinical review of current and emerging therapies". J Am Acad Dermatol. doi:10.1016/j.jaad.2025.04.074. PMID 40345536.
  130. ^ Perez, Sofia M.; Nguyen, Betty; Senna, Maryanne M. (2025). "Efficacy and safety of bicalutamide in female hair loss: A review of the literature". JAAD Reviews. 4: 61–68. doi:10.1016/j.jdrv.2025.03.005.
  131. ^ Tang GT, Zwickl S, Sinclair R, Zajac JD, Cheung AS (September 2023). "Effect of gender-affirming hormone therapy on hair growth: a systematic review of the literature". Clin Exp Dermatol. 48 (10): 1117–1127. doi:10.1093/ced/llad203. PMID 37311161.
  132. ^ Camacho-Martínez FM (March 2009). "Hair loss in women". Semin Cutan Med Surg. 28 (1): 19–32. doi:10.1016/j.sder.2009.01.001 (inactive July 20, 2025). PMID 19341939.{{cite journal}}: CS1 maint: DOI inactive as of July 2025 (link)
  133. ^ Wang C, Du Y, Bi L, Lin X, Zhao M, Fan W (2023). "The Efficacy and Safety of Oral and Topical Spironolactone in Androgenetic Alopecia Treatment: A Systematic Review". Clin Cosmet Investig Dermatol. 16: 603–612. doi:10.2147/CCID.S398950. PMC 10010138. PMID 36923692.
  134. ^ Rastaghi F, Kaveh R, Yazdanpanah N, Sahaf AS, Ahramyanpour N (October 2023). "The Efficacy and Adverse Effects of Corticosteroid Pulse Therapy in Alopecia Areata: A Review Article". Dermatol Pract Concept. 13 (4). doi:10.5826/dpc.1304a255. PMC 10656135. PMID 37992355.
This article is issued from Wikipedia. The text is available under Creative Commons Attribution-Share Alike 4.0 unless otherwise noted. Additional terms may apply for the media files.